Inovio Pharmaceuticals Inc (INO) Hedge Fund & Institutional Holdings (Q2 2026)

INO ranks #4416 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

108 institutions disclose a position in INO, but none treat it as a major bet — even Boxer Capital Management, LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

Susquehanna International Group, LLP has added to its INO position for two straight quarters, increasing it by $1.1M to reach $1.7M today.

Fidelity has trimmed its INO position for two straight quarters, cutting it by $7.8M while still holding $9.3M.

INO is up 0.8% today, and institutions have been net buyers of $4.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

INO reported a net loss of $67.4M over the trailing twelve months.

• Not yet profitable — net loss of $67.4M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$87.8M to -$67.4M
• Operating cash flow was negative, using $88.6M in cash
• Current ratio of 1.40x — below the conventional 1.5x liquidity buffer
• Liabilities run 2.08x equity — a highly leveraged balance sheet worth noting